Loading
A phase 2 trial of A166 in HER2-positive breast cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer is a phase 2 interventional study registered as NCT07299825 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 40 participants planned, started 2024-09-20 and due to reach its primary completion in 2027-09-20. Interventions recorded: A166.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/